Economic Impacts of Heart Failure Management

Heart failure imposes a substantial economic burden on healthcare systems, societies and patients worldwide. Direct medical costs—driven primarily by hospital admissions, advanced imaging, device therapies and pharmacotherapy—account for the majority of expenditure. Indirect costs, including productivity losses from morbidity and premature mortality, further amplify societal impact. Hospitalisation rates remain the dominant cost driver, with the first year after diagnosis incurring peak secondary‐care costs. Medication expenses represent a smaller proportion of total outlay, yet optimised drug regimens that reduce readmissions may yield significant savings. Health‐economic evaluations increasingly assess cost‐effectiveness of novel therapies, remote monitoring and structured care pathways, with an emphasis on value-based strategies. Regional disparities are notable: high-income countries face ageing populations and rising prevalence, while low- and middle-income settings contend with younger cohorts, limited coverage and high out-of-pocket spending. Emerging digital health solutions and predictive analytics offer promise for personalised management and resource allocation. Policymakers and clinicians must balance expenditures against clinical benefit, striving for sustainable models that mitigate hospital burden, enhance quality of life and ensure equitable access to care.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Economic Impacts of Heart Failure Management publication trend

The graph below shows the total number of articles in economic impacts of heart failure management across all publications each year (not limited to Nature Index journals).

Technical terms

Direct costs: Expenditures incurred for medical care, including hospital stays, medications, diagnostics and procedures.

Indirect costs: Economic losses due to reduced productivity, absenteeism, presenteeism and premature mortality.

Cost-of-illness study: An economic analysis framework estimating the total financial impact of a disease on society.

Ejection fraction (EF): Percentage of blood pumped from the left ventricle with each heartbeat; used to classify heart failure phenotypes (reduced, mildly reduced, preserved).

References

1. Healthcare resource utilisation and costs associated with a heart failure diagnosis: a retrospective, population-based cohort study in Sweden. BMJ Open (2021).
2. Healthcare Expenditures Associated with Heart Failure in Saudi Arabia: A Cost of Illness Study. Healthcare (2021).
3. Cost analysis of chronic heart failure management in Malaysia: A multi-centred retrospective study. Frontiers in Cardiovascular Medicine (2022).